Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
BioSyent Gelecekteki Büyüme
Future kriter kontrolleri 1/6
BioSyent is forecast to grow revenue at 12% per annum. EPS is expected to grow by 13.5% per annum.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
13.5%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 48.8% |
| Gelir büyüme oranı | 12.0% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 23 Sep 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
BioSyent's (CVE:RX) Dividend Will Be CA$0.045
Aug 30
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 45 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 41 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 36 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 34 | 7 | 2 | 3 | N/A |
| 3/31/2024 | 33 | 7 | 7 | 7 | N/A |
| 12/31/2023 | 32 | 6 | 5 | 5 | N/A |
| 9/30/2023 | 31 | 6 | 6 | 7 | N/A |
| 6/30/2023 | 29 | 5 | 5 | 5 | N/A |
| 3/31/2023 | 27 | 5 | 3 | 4 | N/A |
| 12/31/2022 | 28 | 5 | 4 | 5 | N/A |
| 9/30/2022 | 28 | 6 | 4 | 5 | N/A |
| 6/30/2022 | 28 | 6 | 6 | 6 | N/A |
| 3/31/2022 | 28 | 6 | 5 | 5 | N/A |
| 12/31/2021 | 29 | 6 | 5 | 5 | N/A |
| 9/30/2021 | 27 | 5 | 5 | 5 | N/A |
| 6/30/2021 | 26 | 4 | 4 | 4 | N/A |
| 3/31/2021 | 24 | 4 | 5 | 6 | N/A |
| 12/31/2020 | 22 | 4 | 7 | 7 | N/A |
| 9/30/2020 | 22 | 4 | 10 | 8 | N/A |
| 6/30/2020 | 23 | 5 | 6 | 7 | N/A |
| 3/31/2020 | 23 | 5 | 4 | 5 | N/A |
| 12/31/2019 | 21 | 4 | 4 | 4 | N/A |
| 9/30/2019 | 22 | 5 | 1 | 4 | N/A |
| 6/30/2019 | 21 | 5 | 4 | 5 | N/A |
| 3/31/2019 | 22 | 6 | 5 | 6 | N/A |
| 12/31/2018 | 22 | 6 | 6 | 6 | N/A |
| 9/30/2018 | 22 | 5 | 6 | 7 | N/A |
| 6/30/2018 | 22 | 6 | 6 | 7 | N/A |
| 3/31/2018 | 21 | 5 | N/A | 7 | N/A |
| 12/31/2017 | 21 | 5 | N/A | 7 | N/A |
| 9/30/2017 | 20 | 5 | N/A | 6 | N/A |
| 6/30/2017 | 19 | 5 | N/A | 5 | N/A |
| 3/31/2017 | 18 | 4 | N/A | 5 | N/A |
| 12/31/2016 | 18 | 4 | N/A | 4 | N/A |
| 9/30/2016 | 17 | 4 | N/A | 3 | N/A |
| 6/30/2016 | 17 | 4 | N/A | 4 | N/A |
| 3/31/2016 | 16 | 4 | N/A | 4 | N/A |
| 12/31/2015 | 15 | 4 | N/A | 3 | N/A |
| 9/30/2015 | 15 | 4 | N/A | 3 | N/A |
| 6/30/2015 | 14 | 4 | N/A | 3 | N/A |
| 3/31/2015 | 13 | 4 | N/A | 3 | N/A |
| 12/31/2014 | 12 | 3 | N/A | 4 | N/A |
| 9/30/2014 | 11 | 3 | N/A | 3 | N/A |
| 6/30/2014 | 10 | 3 | N/A | 2 | N/A |
| 3/31/2014 | 9 | 2 | N/A | 2 | N/A |
| 12/31/2013 | 8 | 2 | N/A | 2 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (2.2%).
Kazançlar ve Piyasa: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market
Yüksek Büyüme Kazançları: Insufficient data to determine if RX's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: RX's revenue (12% per year) is forecast to grow faster than the Canadian market (7% per year).
Yüksek Büyüme Geliri: RX's revenue (12% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time